parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in choroid plexus epithelial cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 13125

receipt 13133: KAZN in dopamine neurons, braak

power: full sample -0.08 (p 0.741, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.08 (p 0.741, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.33 (p 0.188, n 18). could be the mix.
skeptic: leave-one-out range -0.21 to +0.03, sign flips 3; without severely affected donors -0.08 (p 0.741, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for KAZN in dopamine neurons.

case closed: nothing better to follow up.

receipt 13132: KAZN in oligodendrocytes, braak

power: full sample -0.49 (p 0.038, n 18), 95% CI -0.78 to -0.03. the interval excludes zero: something may be there, smaller than a half can see.
confounder: adjusted for sex: -0.45 (p 0.062, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.53 (p 0.024, n 18). not the mix.
skeptic: leave-one-out range -0.67 to -0.43, sign flips 0; without severely affected donors -0.49 (p 0.038, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for KAZN in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts